Evidence map›Paper›PMID 33826081›Full record

Observational studyDrug safety2021

Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan.

Tomoko Funahashi, Toshihiro Koyama, Hideharu Hagiya, Ko Harada, Syunya Iinuma, Soichiro Ushio, Yoshito Zamami, Takahiro Niimura, Kazuaki Shinomiya, Keisuke Ishizawa and 3 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Drug safety, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Tomoko FunahashiDepartment of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 1-1- Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.ORCID 0000-0002-3233-4553
Toshihiro KoyamaDepartment of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan. koyama-oka@umin.ac.jp.ORCID 0000-0002-7755-1754
Hideharu HagiyaDepartment of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.ORCID 0000-0002-5086-1891
Ko HaradaDepartment of General Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Syunya IinumaDepartment of Pharmaceutical Biomedicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.
Soichiro UshioDepartment of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Yoshito ZamamiDepartment of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-1815 Kuramoto, Tokushima, 770-8503, Japan.ORCID 0000-0002-7879-423X
Takahiro NiimuraDepartment of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-1815 Kuramoto, Tokushima, 770-8503, Japan.
Kazuaki ShinomiyaDepartment of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, 180 Nishihamabouji Yamashiro-cho, Tokushima, 770-8514, Japan.
Keisuke IshizawaDepartment of Clinical Pharmacology and Therapeutics, Institute of Biomedical Sciences, Tokushima University Graduate School, 3-1815 Kuramoto, Tokushima, 770-8503, Japan.
Toshiaki SendoDepartment of Pharmacy, Okayama University Hospital, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Shiro HinotsuDepartment of Biostatistics, Sapporo Medical University, South 1, West 17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Mitsunobu R KanoDepartment of Pharmaceutical Biomedicine, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University, 1-1- Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.ORCID 0000-0003-1593-1855
Okayama University · JPTokushima University · JPOkayama University Hospital · JPSapporo Medical University · JPTokushima Bunri University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdverse drug events (ADEs) are a major cause of mortality.

objectiveWe examined long-term trends for ADE-related deaths in Japan.

methodsThis observational study was conducted using the Japanese Vital Statistics from 1999 to 2016. Data for all ADE-related deaths were extracted using International Classification of Diseases, Tenth Revision codes. We analysed ADE-related deaths by age and sex and calculated crude and age-standardised mortality rates (ASMR) per 100,000 people. We used Joinpoint regression analysis to identify significant changing points in mortality trends and to estimate annual percentage change (APC).

resultsIn total, 16,417 ADE-related deaths were identified. The crude mortality rate for individuals aged ≥ 65 years was higher than that of young individuals. The ASMR per 100,000 people increased from 0.44 in 1999 to 0.64 in 2016. The crude mortality rate increased from 0.44 in 1999 to 1.01 in 2016. The APC of ASMR increased at a rate of 2.8% (95% confidence interval [CI] 1.4-4.2) throughout the study period. In addition, crude mortality increased at a rate of 5.7% (95% CI 4.2-7.3) annually from 1999 to 2016. The ADE-related mortality rate was higher for men than for women during the study period.

conclusionsThe number of and trend in ADE-related deaths increased in Japan from 1999 to 2016, particularly in the older population.

Indexed as

Drug-Related Side Effects and Adverse ReactionsFemaleHumansInternational Classification of DiseasesJapanMaleMortalityRegression AnalysisSocieties

Identifiers

PMID33826081
OpenAlexW3142616464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.